for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

财经

Pfizer's, Merck's revenue disappoint investors

Sales of Pfizer's blockbuster drug Ibrance zoomed higher but missed forecasts. Sales of Merck's cancer drug Keytruda catapulted higher, but overall revenue disappointed Wall Street. Fred Katayama reports.

财经

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up